Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first-line triple therapy.
Azucena Arévalo-GalvisAlba Alicia Trespalacios-RangelWilliam A Otero-ReginoPublished in: Helicobacter (2019)
The most frequent polymorphism was extensive PPI metabolizers (62.4%). Effectiveness of guided therapies by susceptibility test was good, yet they can be further improved by customized therapy based on CYP genotype. Therefore, high PPI (80 mg/d) doses are recommended for H pylori eradication therapies in Colombia. ClinicalTrials.gov ID: NCT03650543.